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Abstract
Background: Medulloblastoma is the most common malignant brain tumor of childhood. Improvements in
clinical outcome require a better understanding of the genetic alterations to identify clinically significant biological
factors and to stratify patients accordingly. In the present study, we applied cytogenetic characterization to guide
the identification of biologically significant genes from gene expression microarray profiles of medulloblastoma.
Methods: We analyzed 71 primary medulloblastomas for chromosomal copy number aberrations (CNAs) using
comparative genomic hybridization (CGH). Among 64 tumors that we previously analyzed by gene expression
microarrays, 27 were included in our CGH series. We analyzed clinical outcome with respect to CNAs and
microarray results. We filtered microarray data using specific CNAs to detect differentially expressed candidate
genes associated with survival.
Results: The most frequent lesions detected in our series involved chromosome 17; loss of 16q, 10q, or 8p; and
gain of 7q or 2p. Recurrent amplifications at 2p23-p24, 2q14, 7q34, and 12p13 were also observed. Gain of 8q is
associated with worse overall survival (p = 0.0141), which is not entirely attributable to MYC amplification or
overexpression. By applying CGH results to gene expression analysis of medulloblastoma, we identified three 8q-
mapped genes that are associated with overall survival in the larger group of 64 patients (p < 0.05): eukaryotic
translation elongation factor 1D (EEF1D), ribosomal protein L30 (RPL30), and ribosomal protein S20 (RPS20).
Conclusion: The complementary use of CGH and expression profiles can facilitate the identification of clinically
significant candidate genes involved in medulloblastoma growth. We demonstrate that gain of 8q and expression
levels of three 8q-mapped candidate genes (EEF1D, RPL30, RPS20) are associated with adverse outcome in
medulloblastoma.
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Background
Medulloblastoma is the most common malignant brain
tumor of childhood. Treatment with surgery, radiation,
and chemotherapy successfully cures many patients, but
survivors can suffer significant long-term toxicities affect-
ing their neurocognitive and growth potential. Despite
clinical advances, up to 30% of children with medullob-
lastoma experience tumor progression or recurrence, for
which no curative therapy exists [1]. The lack of more
effective, less toxic therapies and the inability to stratify
patients biologically result from imperfect understanding
of the molecular processes that underlie medulloblast-
oma growth [1-3].
The advent of genomic technologies has permitted a more
global approach to tumor classification, diagnosis, and
prognostication [4-6]. Several medulloblastoma series
have been analyzed for copy number aberrations (CNAs)
with comparative genomic hybridization (CGH), widely
considered a standard method for genome-wide screening
[7-12]. Using CGH, we have determined that gain of the
long arm of chromosome 8 is associated with overall and
progression-free survival of medulloblastoma patients.
Despite its limited resolution, chromosomal CGH can
guide gene expression analysis, suggesting potential onco-
genes or tumor suppressor genes involved in tumor
growth. Our identification of 8q gain as clinically signifi-
cant prompted the search for candidate genes mapped to
that chromosomal region. Previous reports have identi-
fied MYC amplification and overexpression as clinically
significant. However, we did not note such associations in
our series. We investigated the possibility of other 8q-
mapped candidate genes by exploiting the microarray
analysis of an overlapping set of medulloblastoma speci-
mens to complement the scale of our CGH dataset.
Of the 71 tumors we analyzed by CGH, a subset of 27
were among 64 medulloblastomas previously analyzed
using gene expression microarrays, which permitted inte-
grated analysis of both sets of data [6]. We identified three
8q-mapped genes overexpressed in tumors with 8q gain
and whose expression levels were significantly associated
with overall survival in all 64 patients: eukaryotic transla-
tion elongation factor 1D (EEF1D), ribosomal protein
L30 (RPL30), and ribosomal protein S20 (RPS20). We
corroborated the expression of each candidate gene in
microarray analysis by quantitative real time-RTPCR
(qRT-RTPCR). By analyzing expression microarray data
and cytogenetic profiles, we have identified a group of
clinically significant genes involved in translational regu-
lation that display relatively small expression changes and
previously eluded implication by single platform
approaches.
Methods
Patient samples
Seventy-one medulloblastoma samples were obtained fol-
lowing informed consents via Institutional Review Board
(IRB)-approved protocols from patients (aged 7 months –
38 years) diagnosed between 1991 and 2004 at Children's
Hospital (Boston, MA) and Texas Children's Hospital
(Houston, TX). Of these, 27 tumors were also previously
analyzed by expression profiling using oligonucleotide
microarrays [6] [Figure 1]. All specimens were obtained at
the time of diagnosis prior to radiation or chemotherapy
and subjected to histopathologic review according to
WHO criteria [3]. Tumor samples were snap-frozen and
stored in liquid nitrogen.
All patients were initially treated with maximally feasible
surgical resection. Subtotal or partial resection was
achieved in eleven patients. Chemotherapy for most
patients (n = 50) consisted of repeated cycles of cisplatin
and vincristine, with combinations of carboplatin, etopo-
side, cyclophosphamide and/or lomustine [13-16]. The
other twenty-one patients received intensified chemother-
apy cycles (vincristine, cisplatin, cyclophosphamide, and
etoposide) with autologous stem cell support [17].
Patients greater than 36 months old received craniospinal
irradiation 2,400 ± 360 centiGray (cGy) with a tumor
dose of 5,300 ± 720 cGy. For the entire group, median fol-
low up was 36 months (mean 39 months, range 4 – 109).
All studies were performed with the approval of the Com-
mittee for Clinical Investigation and the IRB of Boston
Experimental design Figure 1
Experimental design. Genomic characterization of 71 
medulloblastomas was performed with CGH and the most 
frequent CNAs were subjected to survival analysis. Twenty-
seven tumors also had gene expression profile data, and 
were used to identify differentially expressed genes based on 
tumor chromosomal profiles. For survival analysis, the 64 
medulloblastoma patients were stratified according to the 
expression values for each candidate gene.BMC Cancer 2006, 6:223 http://www.biomedcentral.com/1471-2407/6/223
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Children's Hospital, Harvard Medical School, and the IRB
of Baylor College of Medicine for Texas Children's Hospi-
tal.
Comparative Genomic Hybridization (CGH) and survival 
analysis
Tumor DNA was extracted using the DNeasy Tissue Proto-
col (Qiagen, Valencia, CA). In cases of limited tissue, DNA
was extracted using TRIZOL according to the manufac-
turer's instructions (Invitrogen, Carlsbad, CA), or from
paraffin-embedded tissues using standard methods with
proteinase K digestion, phenol: chloroform extraction,
and ethanol precipitation [18]. Total cellular RNA from a
matching portion of frozen tissue was extracted using TRI-
ZOL or RNeasy (Qiagen). The established medulloblast-
oma cell line Daoy (American Type Culture Collection,
Manassas, VA) was maintained to provide control RNA, as
previously described [19].
Normal metaphase spreads and chromosomal CGH were
performed on 71 tumor specimens as previously
described [20]. Briefly, DNA from normal female human
placental controls and medulloblastoma samples were
labeled by nick-translation with Texas red-5-dUTP and
fluorescein (FITC)-12-dUTP, respectively (Dupont NEN,
Boston, MA), and co-hybridized onto normal metaphase
chromosomes. Images from at least ten to fifteen separate
metaphases were captured by CCD camera (SenSys Pho-
tometrics, Tucson, AZ) mounted on a Nikon Eclipse 800
microscope. The fluorescence signal ratio (FITC:Texas red)
along each chromosome was calculated with Quantitative
Image Processing System (Applied Imaging, Santa Clara,
CA). The average of fluorescence ratios and their 99% con-
fidence intervals were determined for each tumor speci-
men. Threshold ratio values greater than 1.2 and lower
than 0.8 defined tumor gains and losses, respectively.
High-level amplification was defined as fluorescence
ratios in excess of 2.0 at the chromosomal site.
For survival analysis of each CNA, patients were stratified
into two groups based on the presence or absence of the
specific cytogenetic lesion. Only those lesions detected in
a minimum of five patients (7%) were analyzed. Clinical
outcome measures, including overall and progression-free
survival, were determined from the date of diagnosis
using the method of Kaplan and Meier (SPSS v.11; SPSS,
Inc, Chicago, IL). The significance of survival differences
between patient groups was calculated by log-rank test. To
test if 8q gain was an independent prognostic factor, we
also performed multivariate analysis using Cox propor-
tional hazard model for 8q gain with respect to three
other clinical prognostic factors: extent of resection, age
relative to 3 years and metastatic stage at diagnosis.
Gene expression microarray analysis and candidate gene 
identification
Twenty-seven of the 71 tumors characterized by CGH
were previously analyzed for their gene expression pro-
files on Affymetrix HuGeneFL microarrays and were
among the series of 64 reported by Pomeroy et al. [6]. We
normalized the CEL files of 64 tumors and four normal
cerebellar controls. The probe set intensities used for com-
parisons were calculated by model-based expression
index using dCHIP software (v1.3, http://
www.dCHIP.org) [21]. Among the 44 tumors that were
collected subsequently and not included in the previous
report, seven were analyzed on the Affymetrix U133 Plus
2.0 microarrays and their resulting datasets were proc-
essed similarly for direct comparison with parallel qRT-
RTPCR results.
Differentially expressed candidate genes mapped to 8q
were subsequently analyzed for overall and progression-
free survival in the larger group of 64 profiled tumors
based on their expression levels (Kaplan-Meier test, SPSS).
Patients were stratified into two groups based on their
tumor expression level relative to that mean value. Candi-
date genes achieving p values less than 0.05 (log-rank test,
SPSS) were validated using qRT-RTPCR. Fisher's exact test
was used to calculate the significance of the association
between gene expression levels with tumor and clinical
variables.
Quantitative Real Time-RTPCR (qRT-RTPCR)
Tumor RNA was analyzed by qRT-RTPCR performed in a
Bio-Rad iQ4 Multicolor Real Time iCycler (Bio-Rad Labo-
ratories, Hercules, CA). Total cellular RNA was reverse
transcribed with M-MLV Reverse Transcriptase enzyme
(Invitrogen) and oligo-(dT)12, according to the manufac-
turer's recommendations. PCR reactions containing
cDNA, iQ Syber Green Supermix (Bio-Rad), and primers
for  EEF1D, RPL30,  RPS20, MYC, or MYCN  were per-
formed in triplicate for 40 cycles (95°C 15 sec, 60°C 1
min). Amplification products were verified by melting
curves, agarose gel electrophoresis, and sequencing. Copy
numbers were internally normalized to GAPDH expres-
sion, quantitated relative to the Daoy cell line as a calibra-
tor tissue control, and accounting for differences in primer
efficiencies [22]. Results from at least three separate exper-
iments were analyzed. Fisher's exact test was used to calcu-
late the significance of the association between gene
expression levels with tumor and clinical variables. We
determined correlation coefficients (R2) between expres-
sion levels detected by microarray and by qRT-RTPCR
using the Pearson method (relative to the Daoy cell line as
a tissue control). Primer sequences are: EEF1D, sense 5'-
CCCGCGTCCGCCGATTCCTC-3' and antisense 5'-CGCT-
GGCGCCGTTCTCCTG-3';  RPL30  sense, 5'-TGGTGGCT-
GCAAAGAAGAC-3' and antisense 5'-BMC Cancer 2006, 6:223 http://www.biomedcentral.com/1471-2407/6/223
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GCAGTTGTTAGCGAGAATGAC-3';  RPS20  sense, 5'-
CACGCTCCTGCTCCTGACTC-3' and antisense 5'-GCG-
GCTTGTTAGGCTGATTCG-3'; MYC  sense, 5'-TCTGGAT-
CACCTTCTGCTGG-3' and antisense 5'-
TGTTGCTGATCTGTCTCAGG-3'; MYCN sense, 5'-AGAG-
GACACCCTGAGCGATT-3' and antisense 5'-TCTT-
GGGACGCACAGTGATG-3';GAPDH  sense, 5'-
AAGGTGAAGGTCGGAGTCAA-3' and antisense, 5'-AAT-
GAAGGGGTCATTGATGG-3'.
Results
Patient analysis and clinical data
We analyzed overall and progression-free survival for
patient groups stratified by clinical variables such as age,
sex, metastatic (Chang) stage, histologic subtype, and
treatment regimens. Not surprisingly, metastatic disease
at diagnosis displayed a trend toward worse survival
[Table 1]. For other reported risk factors, only age less
than three years was weakly associated with adverse clini-
cal outcome, which could be attributed to the lack of
craniospinal radiation therapy in these patients. Neither
sex nor tumor histology correlated with outcome. Further-
more, different treatment centers and regimens (standard
dose chemotherapy plus radiation vs. intensified chemo-
therapy with autologous stem cell support) were not asso-
ciated with differences in survival.
Overview of CNAs in medulloblastoma
The 71 medulloblastomas analyzed by chromosomal
CGH displayed a variety of CNAs [Figure 2; Table 2]. The
most frequently observed CNAs involved chromosome 17
(i.e. loss of the short arm, 17q gain). The loss of 17p
accompanied by concurrent gain of 17q, consistent with
isochromosome 17q (i17q), was detected in 32% of
tumors. Losses were more frequently observed than gains
and predominated on chromosomes 16, 10, 8, and 11.
We also detected gain of 2p in 22% of tumors, including
5.6% with amplification at 2p23-p24, which was the most
common amplification detected in our series (n = 4).
Other recurrent amplifications were detected at 2q14,
7q34, and 12p13 in two specimens each and at 8q23-q24
in one tumor. Given the resolution of chromosomal CGH
(approximately 10–20 Mb), the 2p23-p24 amplifications
and the 8q23-q24 amplification probably include the
MYCN (2p24.1) and MYC (8q24.12-q24.13) loci, respec-
tively. Amplifications and low copy number gains at
2p23-p24 or 8q23-q24 were not associated with large cell
or anaplastic histology.
CNA-based survival analysis reveals association with gain 
of 8q
To evaluate the clinical significance of common CNAs, we
stratified 71 medulloblastoma patients according to the
presence or absence of specific cytogenetic lesions in their
tumors. Specific CNAs involving 58 chromosomal regions
were observed in a minimum of 7% tumors and used to
stratify patients for Kaplan-Meier survival analysis [Table
2]. The most common lesions, including loss of 17p and/
or gain of 17q, were not significantly associated with out-
come.
Another common CNA, gain of 2p (minimal region 2p23-
p24) detected in 22.5% of tumors (n = 16) displayed a
trend towards worse overall survival (p = 0.0848) [Table 3,
Figure 3]. Amplification at 2p23-p24 seen in 5.6% of
tumors (n = 4) was also associated with worse overall sur-
vival (p = 0.0152). However, gain of 2p without 2p23-p24
amplification in 17% of tumors (n = 12) was not associ-
ated with outcome.
Gain of 8q (minimal region 8q23-q24, in 10% of tumors)
displayed the strongest association with significantly
worse overall and progression-free survival (p = 0.0141
and 0.0004, respectively) [Table 3, Figure 4]. The gain of
8q was also associated with adverse outcome in the well
described high-risk group of patients were younger than
three years of age at diagnosis (n = 14) (p = 0.0023). One
of seven tumors with 8q gain also displayed large cell/ana-
plastic histology with partial loss of 8p23-q22 and ampli-
fication at 8q23-q24, which includes the MYC  locus
(8q24.12-q24.13). When the single case of 8q amplifica-
tion is excluded from the analysis, the other six patients
with gain of 8q22-q24 displayed an even stronger associ-
ation with overall survival (p = 0.0005).
We performed multivariate analysis to test the significance
of 8q gain with regard to outcome. When controlled for
widely accepted prognostic factors (i.e. extent of resection,
age relative to 3 years and metastatic stage at diagnosis),
8q gain is still significantly associated with both PFS and
OS (p = 0.003 and 0.013, respectively) [see Additional file
1].
Adverse outcome is not associated with MYC or MYCN 
expression
To address the potential contribution of MYC or MYCN,
we screened gene expression microarray data of 27 medul-
loblastoma specimens that were among 64 previously
reported tumors [6]. We did not discern significant upreg-
ulation of MYCN or other 2p-mapped gene expression in
the seven tumors with 2p gain or amplification relative to
the twenty tumors without 2p gain [Table 4]. Nor did we
detect an association between MYCN expression and over-
all survival in the larger group of 64 medulloblastomas.
We corroborated the microarray data with qRT-RTPCR in
12 primary medulloblastomas and determined that
MYCN was not significantly overexpressed in tumors with
gain or amplifications of 2p, compared to others (p  =
0.31) [Table 4].B
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Table 1: Patient summary
CLINICAL CHARACTERISTICS 71 tumors analyzed by CGH 27 tumors analyzed by both CGH and microarray 64 tumors analyzed by microarray
Median Age in months (mean; range) 80 (89.4; 7–458) 73 (93.6; 7–458) 74 (99.9; 7–458)
Median Follow-up in months (mean; range) 36 (39; 4–109) 39 (40.2; 7–80) 39 (46; 5–130)
Number of patients < 3 yr old [p value- OS:PFS] 14 [0.139:0.187] 7 [0.542:0.421] 11 [0.406:0.0005]*
STAGE (Chang) – M0: M+ [p value- OS:PFS] 54 : 17 [0.027*:0.111] 20 : 7 [0.058:0.222] 43 : 21 [0.047*:0.012*]
SEX- male: female [p value- OS:PFS] 51 : 20 [0.875:0.532] 18 : 9 [0.729:0.839] 42 : 22 [0.827:0.957]
SURGERY- Gross Total Resection: Subtotal Resection [p value- OS:PFS] 60 : 11 [0.0701:0.386] 18 : 9 [0.028*:0.427] 40 : 24 [0.0502:0.926]
CHEMOTHERAPY- Standard : PBSCT [p value- OS:PFS] 50:21 [0.825:0.972] 27:0 [NA] 64:0 [NA]
HISTOLOGY
Classic [p value- OS:PFS] 30 [0.714:0.619] 16 [0.461:0.996] 44 [0.384:0.377]
Nodular or Desmoplastic [p value- OS:PFS] 21 [0.558:0.731] 8 [0.327:0.987] 15 [0.46:0.564]
Large cell or Anaplastic [p value- OS:PFS] 17 [0.844:0.830] NA NA
Intermediate or Other [p value- OS:PFS] 3 [0.935:0.995] 3 [0.769:0.985] 5 [0.736:0.532]
Abbreviations: CGH, comparative genomic hybridization; OS, overall survival; PFS, progression-free survival; PBSCT, peripheral blood stem cell transplant; NA, not applicable.
Log-rank p values were calculated for OS and PFS.
*Statistically significant p values.BMC Cancer 2006, 6:223 http://www.biomedcentral.com/1471-2407/6/223
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Summary of Comparative Genomic Hybridization Figure 2
Summary of Comparative Genomic Hybridization. Ideogram showing genetic imbalances detected in 71 medulloblast-
oma by comparative genomic hybridization (CGH). Red bars on the left of the chromosomes represent losses and green bars 
on the right correspond to gains of chromosomal regions in tumors; amplifications are depicted as bold green bars. Multiple 
cases with the same CNA are grouped as thick bars, with total number of cases displayed at the top.BMC Cancer 2006, 6:223 http://www.biomedcentral.com/1471-2407/6/223
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We also examined the possible contribution of MYC
expression to the clinical significance of 8q gain. Higher
levels of MYC expression correlated with slightly worse
outcome among the larger group of 64 medulloblasto-
mas, although failed to achieve statistical significance (in
agreement with previous results) [6]. In addition, MYC
was not consistently overexpressed in microarray-ana-
lyzed tumors with 8q gain (n = 3) [Table 4]. We quanti-
tated MYC in twelve available tumor specimens with qRT-
RTPCR and found that MYC was not significantly upregu-
lated in the two tumors with 8q gain (t = 0.49). Not sur-
prisingly, the one tumor with 8q23-q24 amplification
displayed the highest MYC level, while low copy number
gains of 8q did not correlate with higher MYC levels in
either microarray- or qRT-RTPCR-tested specimens. As
tested by qRT-RTPCR, relative MYC expression correlated
highly with microarray results (R2 = 0.99). Overall, these
data suggest that MYC expression, like 8q amplification, is
Table 2: Most Common Chromosomal Copy Number Aberration Among 71 Medulloblastomas.
Chromosome Loss Number (%) p value, log-rank [OS: PFS]
17p loss 36 (50%)* 0.544: 0.816
17p loss and 17q gain (consistent with isochromosome 17q) 23 (32%)* 0.704: 0.874
16q loss 29 (40%) 0.707: 0.889
10q loss 25 (35%) 0.356: 0.252
8p loss 24 (34%) 0.581: 0.423
16p loss 22 (31%) 0.744: 0.736
6q loss 16 (22%) 0.741: 0.345
10p loss 16 (22%) 0.325: 0.386
9q loss 16 (22%) 0.999: 0.703
11p loss 15 (21%) 0.201: 0.212
19p loss 13 (18%) 0.332: 0.282
3q loss 13 (18%) 0.899: 0.439
6p loss 13 (18%) 0.506: 0.095
11q loss 13 (18%) 0.330: 0.375
13q loss 10 (14%) 0.966: 0.611
17q loss 10 (14%) 0.918: 0.889
15q loss 8 (11%) 0.064: 0.596
1p loss 8 (11%) 0.061: 0.167
20q loss 8 (11%) 0.992: 0.780
X loss 8 (11%) 0.958: 0.613
3p loss 7 (10%) 0.476: 0.343
21q loss 7 (10%) 0.397: 0.573
Chromosome Gain Number (%) p value, log-rank [OS: PFS]
17q gain 34 (48%)* 0.794: 0.340
17q gain and 17p loss (consistent with isochromosome 17q) 23 (32%)* 0.704: 0.874
7q gain 21 (30%) 0.927: 0.366
2p gain 16 (22%) 0.394: 0.526
7p gain 16 (22%) 0.394: 0.195
18q gain 11 (15%) 0.896: 0.842
X gain 10 (14%) 0.786: 0.868
2q gain 10 (14%) 0.166: 0.356
17p gain 9 (13%) 0.545: 0.885
5p gain 9 (13%) 0.863: 0.688
18p gain 9 (13%) 0.963: 0.652
1q gain 8 (11%) 0.242: 0.088
9p gain 8 (11%) 0.913: 0.893
19 gain 8 (11%) 0.480: 0.403
8q gain 7 (10%) 0.0141**: 0.0004**
3q gain 7 (10%) 0.212: 0.464
5q gain 7 (10%) 0.657: 0.790
6q gain 7 (10%) 0.551: 0.990
* In 23 cases, 17q gain was detected with concurrent 17p loss, and was consistent with i17q.
** Statistically significant differences by log-rank testing.BMC Cancer 2006, 6:223 http://www.biomedcentral.com/1471-2407/6/223
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not entirely responsible for the association of 8q gain with
survival.
Independent of 8q status, adverse outcome is associated 
with expression of 8q-mapped genes: EEF1D, RPL30, and 
RPS20
Since MYC amplification and expression were not associ-
ated with overall survival in our series, we analyzed gene
expression data to identify other candidate genes affected
by this specific CNA. Of the 27 medulloblastomas with
both CGH and microarray data, 11% displayed 8q gain,
whose expression profiles were compared to the other
89% of tumors. Of the 149 genes with at least 1.5-fold dif-
ferential expression levels, 27 genes were upregulated in
8q gain tumors and five genes mapped to 8q. Since gene
dosage effects related to chromosomal gains may contrib-
ute to higher relative gene expression, we sought to define
those candidate genes significantly associated with clini-
cal outcome.
In the larger group of 64 microarray-profiled tumors, the
expression levels of three of five 8q-mapped genes were
adversely associated with overall and progression-free sur-
vival: eukaryotic translation elongation factor 1D
(EEF1D;p values, 0.014 (OS) and 0.0085 (PFS), log-rank),
ribosomal protein L30 (RPL30;p values, 0.014 (OS) and
0.0018 (PFS)), and ribosomal protein S20 (RPS20;p val-
ues, 0.0005 (OS) and 0.0213 (PFS)) [Table 4; Figures 5, 6,
7]. In fact, we detected elevated levels of these genes in
many tumors without 8q gain. This suggests that not only
do these candidate genes contribute to outcome in
patients with 8q gain tumors, but also in those regardless
of their cytogenetic profiles. The expression levels of
EEF1D, RPL30, and RPS20 did not correlate with MYC
expression in the 64 microarray-profiled tumors.
Because the 64 tumor specimens profiled on Affymetrix
HuGeneFL, were unavailable for further analysis by qRT-
RTPCR, we could not validate candidate gene expression
directly. Alternatively, we assayed the expression of
EEF1D, RPL30, and RPS20 with qRT-RTPCR in twelve
available medulloblastoma specimens, including those
analyzed by Affymetrix U133 Plus 2.0 microarrays [Table
4]. To corroborate the tumor profiles, we compared the
expression of each candidate gene by qRT-RTPCR with the
new set of microarray-generated data on Affymetrix U133
Plus 2.0. As expected, each candidate gene demonstrated
a broader range of differential expression by qRT-RTPCR
than by microarray, consistent with signal compression
[23]. Our qRT-RTPCR results correlated well with the
expression patterns noted in microarray data (R2, 0.53–
0.90) [Table 4], indicating that observed expression levels
detected by microarray analysis likely reflect tumor differ-
ences.
Discussion
We report the results of our CGH analysis of a large series
of medulloblastoma and the application of CNA-based
outcome analysis of expression datasets to identify candi-
date genes. The relative frequencies of various CNAs are
consistent with previous CGH reports [7,9-12]. The most
common aberrations involved chromosome 17, includ-
ing loss of 17p and gain of 17q, which were not signifi-
Survival analysis of patients stratified by gain of the long arm  of chromosome 2 Figure 3
Survival analysis of patients stratified by gain of the 
long arm of chromosome 2. Kaplan-Meier analysis of 
overall survival (OS) in 71 patients with medulloblastoma 
stratified by gain of 2p: sixteen patients with 2p gain com-
pared to 55 others without 2p gain. Follow-up is expressed 
as time from diagnosis in months.
Table 3: Copy Number Aberrations associated with overall and progression-free survival.
Copy Number Aberration n Overall Survival p value (log-rank) Progression-Free Survival p value (log-rank)
2p gain (including amplifications) 12 (16) 0.5257 (0.0848) 0.3938 (0.0701)
8q gain (including amplifications*) 6 (7) 0.0005** (0.0141**) < 0.0001** (0.0004**)
* Multivariate analysis controlling for clinical variables (i.e. metastatic stage, degree of resection, and age relative to 3 years) revealed statistically 
significant differences in OS (p value, 0.013) and PFS (p value, 0.003).
** Statistically significant differences by log-rank testing.BMC Cancer 2006, 6:223 http://www.biomedcentral.com/1471-2407/6/223
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cantly associated with outcome in our series. Several
reports have studied the clinical significance of CNAs, in
particular involving chromosome 17, but with discordant
results. Loss of 17p correlated with survival in several
series [24-27]. Mendrzyk et al [28] and Pan et al [10] have
described adverse outcomes associated with combined
17p loss and 17q gain, as in iso17q, respectively. Negative
studies include those of Biegel et al [29], Emadian et al
[30], Jung et al [31], and Nicholson et al [32]. In general,
these studies evaluated fewer samples or follow-up was
limited. In addition, multiple clinical factors probably
contribute to discrepancies among different series.
Our CGH-based outcome analysis reveals a significant
association between 8q gain (minimal common region
8q23-q24) and worse overall survival, confirmed by mul-
tivariate analysis by controlling for three known prognos-
tic factors. We detected 8q gain in only seven cases of the
71 tumor specimens analyzed. The relatively low fre-
quency of 8q gain probably prevented detection of its clin-
ical significance in other series. MYC amplification has
been identified as a marker of poor prognosis, but previ-
ous studies did not further characterize cytogenetic
changes involving 8q. In fact, excluding the only patient
with tumor amplification at 8q23-q24 from the outcome
analysis actually strengthens the association of 8q gain
with overall survival. Although only a minority of speci-
mens was available for confirmatory qRT-RTPCR quanti-
tation, in those tumors tested, MYC levels correlated well
with microarray results. MYC expression levels, however,
were not associated with survival in our series, in contrast
with previous reports [33]. Overall, our results indicate
that biological factors associated with 8q gain other than
MYC achieve clinical significance in our series of medul-
loblastoma patients. Due to the relatively low frequency
of 8q gain, however, its prognostic significance requires
confirmation in studies with larger sample size.
Our CGH and gene expression analysis indicate that other
genes mapped to 8q may contribute to clinical outcome.
We screened microarray profiles in an overlapping subset
of tumors to identify differentially expressed candidate
genes overexpressed in specimens with 8q gain. The
expression of three candidate genes were associated with
overall and progression-free survival: EEF1D, RPL30, and
RPS20. By analyzing the larger group of 64 patients, we
confirmed the association of these candidate genes with
outcome. In fact, among the 64 patients, higher expres-
sion of EEF1D, RPL30, and RPS20 correlated with worse
overall and progression-free survival regardless of cytoge-
netic profile. Since we also detected overexpression of
these candidate genes in tumor samples without 8q gain,
alternate mechanisms of induction may otherwise con-
tribute to tumor phenotype and clinical outcome.
These candidate genes represent a novel group involved in
translational regulation and have not been previously
associated with outcome in medulloblastoma. Although
we previously reported that RPL30 expression was associ-
ated with classic histology, the smaller expression differ-
ences precluded prior detection and association with
survival [6]. In that study, we employed a two-class com-
parison of array profiles based on an unsupervised cluster-
ing algorithm (self-organizing map) to define a multi-
gene predictor of adverse outcome. The multi-gene predic-
tor included several other ribosomal genes, but did not
include  EEF1D,  RPL30, or RPS20. All three candidate
genes are involved in ribosomal functions: RPS20 encodes
a component of the 60S ribosomal subunit, and RPL30
part of the 40S subunit. The EEF1D protein contributes to
delivery of t-RNA to ribosomes. The overexpression of
EEF1D has been associated with advanced tumor stage in
gastrointestinal carcinomas and EEF1D  reportedly dis-
plays oncogenic properties in vitro [34-36]. This supports
the hypothesis that increased expression of ribosomal
genes confers a growth advantage [37].
Indeed, accumulating evidence indicates that aberrant
regulation of ribosomes, their components, and their
functions can be linked to cellular transformation. Several
oncogenes and tumor suppressor genes, including MYC
Survival analysis of patients stratified by gain of the long arm  of chromosome 8 Figure 4
Survival analysis of patients stratified by gain of the 
long arm of chromosome 8. Kaplan-Meier analysis of 
overall survival (OS) in 71 patients with medulloblastoma 
stratified by gain of 8q: seven patients with 8q gain and 64 
others without 8q gain. Follow-up is expressed as time from 
diagnosis in months.B
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Table 4: Genes of interest mapped to 8q and 2p.
Gene Cytoband Affymetrix probe set Overall Survival 
(p value1)
Progression- Free 
Survival (p value1)
Mean Fold Change by 
Microarray (ratio of tumors 
with CNA: tumors without 
CNA)2 (p value)
Ribosomal protein S20 (RPS20) 8q12 HG1800-HT1823_at 0.0005* 0.0213*1 . 5 8   (0.025)**
Ribosomal protein L30 (RPL30) 8q22 HG2873-HT3017_at 0.014* 0.0018*1 . 7 8   (0.0162)**
Euskaryotic translation elongation factor 1 delta (EEF1D) 8q24.3 Z21507_at 0.014* 0.0085*1 . 7 1  ( 0.0089)**
MYC 8q24.12-q24.13 L00058_at and HG3523-HT4899_s_at 0.218–0.378 0.223–0.506 1.35 and 2.99 (0.38 and 0.26)
MYCN 2p24.1 M13241_at 0.403 0.661 1.56 (0.31)
1 Kaplan-Meier analysis of 64 patients stratified by microarray-based gene expression levels using Affymetrix HuGeneFL microarrays. Significance determined by log-rank test.
2 Ratio calculated from expression levels in 27 patient samples with and without the specific CNA (8q or 2p gain), using HuGeneFL microarrays. Significance determined by log-rank test.
* Statistically significant differences in overall survival based on microarray expression levels.
** Statistically significant differences in microarray expression levels among tumors analyzed by both CGH and microarray.BMC Cancer 2006, 6:223 http://www.biomedcentral.com/1471-2407/6/223
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and MYCN, regulate the expression of rRNA and ribos-
omal proteins [37]. Not surprisingly, cancer cells display
increased metabolism and protein synthesis, which
requires upregulated ribosomal proteins and rRNA [37].
Since ribosomal proteins and translation factors directly
regulate protein synthesis, influencing ribosomal biogen-
esis is one of the possible mechanisms by which cellular
growth controls can be disrupted, resulting in increased
proliferation. It remains unclear precisely how deregula-
tion of rRNA and ribosomal functions are involved in
tumor formation or progression. Nonetheless, our results
suggest that better appreciation of the relative contribu-
tions of EEF1D, RPL30, RPS20, and their associated regu-
latory mechanisms will impact our understanding of
medulloblastoma biology. The identification of these
three candidate genes indicates that specific mechanisms
of ribosomal biosynthesis and translational regulation are
certainly worthy of future study in medulloblastoma.
Conclusion
In summary, our CGH survey of 71 medulloblastomas
indicates that the gain of 8q is adversely associated with
overall and progression-free survival in patients with
medulloblastoma. We applied our cytogenetic results to
guide the expression analysis of a subset of twenty-seven
tumors and subsequent outcome analysis in the larger
group of 64 tumors. By exploiting these complementary
genomic datasets, we have implicated the expression of
three 8q-mapped candidate genes (EEF1D, RPL30, and
RPS20) as adversely associated with overall and progres-
sion-free survival, independent of cytogenetic profile. Our
results indicate the potential for hypothesis-generation by
integrating these global approaches, so that more selective
methods may now be applied in future studies of their
contributions to tumor biology and clinical outcome.
Abbreviations
CGH, comparative genomic hybridization; CNA, copy
number aberration; EEF1D, eukaryotic translation elonga-
tion factor 1D; qRT-RTPCR, quantitative real-time reverse
transcription polymerase chain reaction; RPL30, ribos-
omal protein L30; RPS20, ribosomal protein S20.
Survival analysis of patients stratified by expression of ribos- omal protein L30 (RPL30) Figure 6
Survival analysis of patients stratified by expression 
of ribosomal protein L30 (RPL30). Kaplan-Meier analysis 
of overall survival in 64 patients with medulloblastoma based 
on Hu6800FL array data for the 8q-mapped candidate gene, 
ribosomal protein L30 (RPL30). We calculated the mean 
between the median expression level of tumors with 8q gain 
and the median level of those without it. Patients were strat-
ified into two groups based on their tumor expression level 
relative to that mean. Follow-up is expressed as time from 
diagnosis in months.
Survival analysis of patients stratified by expression of  eukaryotic translation elongation factor 1 delta (EEF1D) Figure 5
Survival analysis of patients stratified by expression 
of eukaryotic translation elongation factor 1 delta 
(EEF1D). Kaplan-Meier analysis of overall survival in 64 
patients with medulloblastoma based on Hu6800FL array 
data for the 8q-mapped candidate gene, eukaryotic transla-
tion elongation factor 1 delta (EEF1D). We calculated the 
mean between the median expression level of tumors with 
8q gain and the median level of those without it. Patients 
were stratified into two groups based on their tumor expres-
sion level relative to that mean. Follow-up is expressed as 
time from diagnosis in months.BMC Cancer 2006, 6:223 http://www.biomedcentral.com/1471-2407/6/223
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